AbstractWe assessed the comparative efficacy of empirical therapy with beta-lactam plus macrolide vs. beta-lactam plus doxycycline for the treatment of community-acquired pneumonia (CAP) among patients in the Australian Community-Acquired Pneumonia Study. Both regimens demonstrated similar outcomes against CAP due to either ‘atypical’ (Chlamydophila, Legionella or Mycoplasma spp.) or typical bacterial pathogens
AbstractThe relative efficacy, safety and ecological implications of macrolides vs. quinolones in th...
Community-acquired pneumonia (CAP) ranks 4th in all-cause morbidity and is the 3rd leading cause of ...
AbstractFor patients hospitalized with pneumonia, guidelines provide empirical antibiotic recommenda...
AbstractWe assessed the comparative efficacy of empirical therapy with beta-lactam plus macrolide vs...
IMPORTANCE: The clinical benefit of adding a macrolide to a β-lactam for empirical treatment of mode...
Background. Available data on the etiology of community-acquired pneumonia (CAP) in Australia are ve...
(See the editorial commentary by Mandell on pages 1522–4) Background. Available data on the etiology...
Background Current guidelines recommend a β-lactam plus a macrolide or fluoroquinolone monotherapy ...
BACKGROUND: For years, monotherapy with a beta-lactam antibiotic (penicillin, amoxicillin or second-...
BACKGROUND: For years, monotherapy with a beta-lactam antibiotic (penicillin, amoxicillin or second-...
Antibiotic combinations that include macrolides have shown lower mortality rates than β-lactams in m...
Community-acquired pneumonia (CAP) is a common and potentially serious illness that is associated wi...
Objectives: British Thoracic Society guidelines recommend clarithromycin in addition to beta-lactam ...
Background: We compared beta-lactam-macrolide (combination) therapy vs. beta-lactam alone (monothera...
Background: Community-acquired pneumonia (CAP) has a potential complication of bacteremia. The objec...
AbstractThe relative efficacy, safety and ecological implications of macrolides vs. quinolones in th...
Community-acquired pneumonia (CAP) ranks 4th in all-cause morbidity and is the 3rd leading cause of ...
AbstractFor patients hospitalized with pneumonia, guidelines provide empirical antibiotic recommenda...
AbstractWe assessed the comparative efficacy of empirical therapy with beta-lactam plus macrolide vs...
IMPORTANCE: The clinical benefit of adding a macrolide to a β-lactam for empirical treatment of mode...
Background. Available data on the etiology of community-acquired pneumonia (CAP) in Australia are ve...
(See the editorial commentary by Mandell on pages 1522–4) Background. Available data on the etiology...
Background Current guidelines recommend a β-lactam plus a macrolide or fluoroquinolone monotherapy ...
BACKGROUND: For years, monotherapy with a beta-lactam antibiotic (penicillin, amoxicillin or second-...
BACKGROUND: For years, monotherapy with a beta-lactam antibiotic (penicillin, amoxicillin or second-...
Antibiotic combinations that include macrolides have shown lower mortality rates than β-lactams in m...
Community-acquired pneumonia (CAP) is a common and potentially serious illness that is associated wi...
Objectives: British Thoracic Society guidelines recommend clarithromycin in addition to beta-lactam ...
Background: We compared beta-lactam-macrolide (combination) therapy vs. beta-lactam alone (monothera...
Background: Community-acquired pneumonia (CAP) has a potential complication of bacteremia. The objec...
AbstractThe relative efficacy, safety and ecological implications of macrolides vs. quinolones in th...
Community-acquired pneumonia (CAP) ranks 4th in all-cause morbidity and is the 3rd leading cause of ...
AbstractFor patients hospitalized with pneumonia, guidelines provide empirical antibiotic recommenda...